Sanofi: invests E40m in Lyon Gerland site

(CercleFinance.com) - Sanofi announces a E40m investment in its Lyon Gerland biomanufacturing site dedicated to immunology.


Sanofi thus continues to support the production in France of Thymoglubulin, a drug used notably in transplantation, and anticipates future needs in biomanufacturing by localising in France the production of a drug for type 1 diabetes - TZIELD.

As part of this investment, E25m will be devoted to the production and development of the second generation of its polyclonal antibody, which is crucial for transplant patients.

In addition, an investment of over E15m is planned to internalise and localise, in France, the production of monoclonal antibodies for the treatment of type 1 diabetes in the pre-clinical and clinical stages of the disease.

Sanofi said that with this significant investment, we are strengthening our footprint and leadership in biomanufacturing from France to serve our ambitions in immunology. Our Lyon Gerland site already plays a central role in Lyon's life sciences ecosystem, and this investment is a further step in accelerating its role in serving patients in France and around the world.


Copyright (c) 2024 CercleFinance.com. All rights reserved.